RESEARCH Open Access



Importance of preoperative total colonoscopy and endoscopic resection after self-expandable metallic stent placement for obstructive colorectal cancer as a bridge-to-surgery

Shuichi Itonaga¹, Shohei Hamada¹, Eikichi Ihara², Hitoshi Honma¹, Hiroki Fukuya¹, Akito Ookubo¹, Taisuke Sasaki¹, Daisuke Yoshimura¹, Makoto Nakamuta¹, Yorinobu Sumida³ and Naohiko Harada^{1*}

Abstract

Background and aim Colonic self-expandable metallic stent (SEMS) placement enables preoperative total colonoscopy (TCS) in patients with obstructive colorectal cancer. Following SEMS placement, it is possible to assess the presence or absence of synchronous proximal colon cancers and perform preoperative endoscopic resection (ER) for neoplastic lesions proximal to the primary lesion. The objective of this study was to determine the usefulness and safety of preoperative TCS and ER after SEMS placement in patients with obstructive colorectal cancer.

Methods From April 2016 to March 2022, we enrolled 100 patients with obstructive colorectal cancer who underwent SEMS placement, including 86 patients who underwent preoperative TCS after SEMS placement. Complications associated with preoperative TCS and ER after SEMS placement and the characteristics of the neoplastic lesions were assessed.

Results The success rate of SEMS placement as bridge-to-surgery was 98.0%; six patients had associated complications. Preoperative TCS was performed 8 (range: 1–30) days after SEMS placement. Four patients had synchronous advanced cancers. Nine non-advanced synchronous cancers, 116 adenomas, and 18 sessile-serrated lesions were treated by preoperative TCS and ER after SEMS placement. No procedure-related complications, namely stent migration, bleeding, and perforation were observed. Forty-five patients underwent follow-up TCS 1 year after surgery. Only one patient with submucosal invasive cancer required a second surgery.

Conclusions Preoperative TCS and ER after SEMS placement was performed with no complications. This approach allows preoperative evaluation of the entire colon and the treatment of precancerous lesions. (240 words)

Keywords Obstructive colorectal cancer, Bridge-to-surgery, Self-expandable metallic stent, Synchronous cancers, Endoscopic resection

*Correspondence: Naohiko Harada harada.naohiko.ea@mail.hosp.go.jp

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Itonaga et al. BMC Gastroenterology (2023) 23:251 Page 2 of 5

Introduction

Placement of colonic self-expandable metallic stents (SEMS) is widely performed in patients with obstructive colorectal cancer as a bridge-to-surgery (BTS). This procedure avoids emergency surgery by resolving obstruction to the passage of stool and obstructive enterocolitis. Colonic SEMS placement for BTS not only minimizes postoperative complications and the risk of colostomy compared with emergency surgery [1-3], but also provides similar surgical outcomes and long-term prognosis compared with non-obstructive colorectal cancer [4]. Another important problem with obstructive colorectal cancer is the possibility of synchronous colon cancers proximal to the primary lesion. Assessing patients for synchronous proximal colonic cancers is very important because this issue affects the operative strategy for the primary lesion. In this regard, an important advantage of colonic SEMS placement is that this approach permits total colonoscopy (TCS) after preparation with osmotic laxatives before surgical treatment of the primary lesion. Preoperative TCS after colonic SEMS placement enables the assessment of the presence or absence of synchronous proximal colon cancers. This approach also permits preoperative endoscopic resection (ER), if applicable, for neoplastic lesions proximal to the primary lesion by cold snare polypectomy (CSP), endoscopic mucosal resection (EMR), or endoscopic submucosal dissection (ESD). The preoperative pathological diagnoses of synchronous colonic neoplastic lesions is important when considering the operative strategy for the primary lesion. The objective of this study was to determine the usefulness and safety of preoperative TCS and ER after colonic SEMS placement in patients with obstructive colorectal cancer.

Methods

From April 2016 to March 2022, 100 patients with obstructive colorectal cancer admitted to our hospital underwent colonic SEMS placement for BTS. The Niti-S colonic stent (Century Medical, Co. Ltd., Tokyo, Japan) or HANAROSTENT Naturfit colonic stent (Boston

Table 1 Locations of the colonic SEMS placed for obstructive colorectal cancers

| Location | Number of cases | |
|----------------------|-----------------|--|
| Cecum (n) | 3 | |
| Ascending colon (n) | 5 | |
| Transverse colon (n) | 12 | |
| Descending colon (n) | 14 | |
| Sigmoid colon (n) | 41 | |
| Rectum, RS (n) | 20 | |
| Rectum, Ra (n) | 3 | |
| Total (n) | 98 | |

SEMS, self-expandable metallic stent; RS, rectosigmoid colon; Ra, rectum above the peritoneal reflection

Scientific, Marlborough, MA, USA) were used. In all cases, plain abdominal X-rays were obtained 2 days after colonic SEMS placement to confirm sufficient expansion. Eighty-six patients underwent preoperative TCS after preparation with an osmotic laxative (MoviPrep®; Salix Pharmaceuticals, Morrisville, NC, USA). Forty-seven patients underwent ER, which comprised CSP, EMR, or ESD, after stent placement (Table 1). The ER method was chosen on the basis of the lesion size (CSP: < 9 mm, EMR: 10-20 mm, ESD: > 20 mm). Regarding TCS after colonic SEMS placement, the colonoscope was inserted and ER was performed as gently and carefully as possible using small-caliber colonoscopes (PCF-PQ260L or PCF-H290ZI; Olympus, Co. Ltd., Tokyo, Japan). Patients underwent postoperative TCS 1 year after surgery. The data were expressed as median (interquartile range), if applicable. The approval of the ethics committee review board in our hospital was obtained for this study.

Results

Of the 100 patients with obstructive colorectal cancer, colonic SEMS placement for BTS was performed successfully in 98 patients (Fig. 1). The success rate of colonic SEMS placement for BTS was 98.0%. The locations of the colonic SEMS are shown in Table 1. Five patients development complications (stenosis in one, perforation in four) associated with stent placement (Table 2). Preoperative TCS was performed 8 (range: 1-30) days after SEMS placement in 86 patients. Obstructive enteritis was observed in 12 patients, none of whom had abdominal symptoms, such as abdominal pain or vomiting, associated with preparation using osmotic laxatives (Table 3). Preoperative TCS after SEMS placement revealed that four patients had synchronous advanced cancers (Table 3). One hundred and two neoplastic lesions from 38 patients were treated by CSP (Table 4); 38 neoplastic lesions from 19 patients were treated by EMR (Table 5), and 3 neoplastic lesions from 3 patients were treated by ESD (Table 6). There were no complications, namely stent migration, bleeding, and perforation, associated with endoscopic insertion and treatment. Following preoperative TCS and ER after SEMS placement, 9 non-advanced synchronous cancers, 116 adenomas, and 18 sessileserrated lesions were treated. Among 86 patients who underwent TCS before surgery, surgery was performed 25 (range: 8-47) days after colonic SEMS placement. Forty-five patients underwent follow-up TCS within 1 year after surgery. Regarding neoplastic lesions larger than 10 mm, seven lesions from six patients (cancer: two, adenoma: five) were detected (Table 7). Only one patient, with submucosal invasive cancer on the proximal side of the anastomosis, required a second surgery. The remaining six lesions were treated endoscopically by EMR or ESD.




Fig. 1 Clinical course of the patients with obstructive colorectal cancers

CSP was performed for 102 lesions (38 patients) including 1 cancerous lesion

EMR was performed for 38 lesions (19 patients) including 6 cancerous lesions (5patients)

ESD was performed for 3 lesions (3 patients) including 2 cancerous lesions (2 patients)

Nine synchronous non-advanced cancers were resected in eight patients

SEMS: self-expandable metallic stent; BTS: bridge-to-surgery; TCS: total colonoscopy; CSP: cold snare polypectomy; EMR: endoscopic mucosal resection;

ESD: endoscopic submucosal dissection

Table 2 Complications associated with colonic SEMS placement among 98 patients with obstructive colorectal cancer

| Adverse events after placement | Number of cases | |
|--------------------------------|-----------------|--|
| Obstruction (n) | 0 | |
| Stenosis (n) | 1 | |
| Migration (n) | 4 | |
| Perforation (n) | 0 | |
| Total events rate (%) | 5.1 | |

SEMS, self-expandable metallic stent

Discussion

In obstructive colorectal cancer, the reported frequency of synchronous colon cancers is 9% [5]. Recently, preoperative TCS after colonic SEMS placement was associated with a non-negligible chance of detection of synchronous colon cancers proximal to the primary lesion [6, 7]. Additionally, preoperative TCS after colonic SEMS placement permits the assessment of the presence or absence of synchronous colon cancers as well as biopsy and/or ER

Table 3 Characteristics of the patients who underwent total colonoscopy after colonic SEMS placement (n = 86)

| Median days from stent placement to TCS (range) | 8 (1–30) |
|---|-----------|
| Number of obstructive colitis cases detected during TCS (n) | 12 |
| Number of simultaneously detected synchronous advanced cancers (lesions/patients) | 4 /4 |
| Number of resected synchronous non-advanced cancers (lesions/patients) | 9 /8 |
| Number of total synchronous cancer (lesion/patient) | 13 /11 |
| Median days from stent placement to surgery (range) | 25 (8–47) |
| Number of patients who underwent TCS within 1 year after surgery (n) | 45 |

SEMS, self-expandable metallic stent; TCS, total colonoscopy

Table 4 Characteristics of 102 neoplastic lesions from 38 patients resected by CSP after colonic SEMS placement

| Location | Carcinoma (invasion depth) | Adenoma | SSL | Total |
|----------------------|----------------------------------|---------|-----|-------|
| Cecum (n) | 0 | 6 | 4 | 10 |
| Ascending colon (n) | 1 (unclear) | 18 | 2 | 21 |
| Transverse colon (n) | 0 | 23 | 4 | 26 |
| Descending colon (n) | 0 | 7 | 0 | 7 |
| Sigmoid colon (n) | 0 | 22 | 3 | 25 |
| Rectum,RS (n) | 0 | 2 | 1 | 3 |
| Rectum, Ra (n) | 0 | 5 | 0 | 5 |
| Rectum, Rb (n) | 0 | 3 | 2 | 5 |
| Total (n) | 1 | 86 | 15 | 102 |

CSP, cold snare polypectomy; SEMS, self-expandable metallic stent; SSL, sessile serrated lesion; RS, rectosigmoid colon; Ra, rectum above the peritoneal reflection; Rb, rectum below the peritoneal reflection

Table 5 Characteristics of 38 neoplastic lesions from 19 patients resected by EMR after colonic SEMS placement

| Location | Carcinoma (invasion depth) | a Adenoma | SSL | Total |
|----------------------|----------------------------------|-----------|-----|-------|
| Cecum (n) | 0 | 1 | 1 | 2 |
| Ascending colon (n) | 1(M) | 4 | 1 | 7 |
| Transverse colon (n) | 0 | 7 | 0 | 7 |
| Descending (n) | 0 | 6 | 1 | 7 |
| Sigmoid colon (n) | 5(M) | 5 | 0 | 10 |
| Rectum, RS (n) | 0 | 2 | 0 | 2 |
| Rectum, Ra (n) | 0 | 1 | 0 | 1 |
| Rectum, Rb (n) | 0 | 3 | 0 | 3 |
| Total (n) | 6 | 29 | 3 | 38 |

EMR, endoscopic mucosal resection; SEMS, self-expandable metallic stent; SSL, sessile serrated lesion; RS, rectosigmoid colon; Ra, rectum above the peritoneal reflection; Rb, rectum below the peritoneal reflection

Table 6 Characteristics of 3 neoplastic lesions resected by ESD after colonic SEMS placement

| Location | Cancer (invasion depth) | Adenoma | |
|----------------------|-------------------------|---------|--|
| Transverse colon (n) | 1 (in situ) | 0 | |
| Rectum, Ra (n) | 1 (submucosal, 2000 μm) | 0 | |
| Rectum Rb (n) | 0 | 1 | |

ESD, endoscopic submucosal dissection; SEMS, self-expandable metallic stent; Ra, rectum above the peritoneal reflection; Rb, rectum below the peritoneal

[8]. This approach can provide information to determine the operative strategy for the primary lesion. In the present study, preoperative TCS and ER after colonic SEMS placement revealed synchronous colon cancers in 11 patients (12.7%). Both the expanded diameter of SEMS and the colonoscope caliber are key to success or failure with preoperative TCS after colonic SEMS placement [9]. In the present study, by gently and carefully inserting small-caliber colonoscopes, no complications were associated with preoperative TCS and ER after colonic SEMS placement.

Table 7 Characteristics of neoplastic lesions larger than 10 mm detected in 45 patients who underwent follow-up colonoscopy within 1 year after surgery

| VVICIIIII | year arter st | argery | | |
|----------------|-------------------|---|---------------------|--|
| Patient age | Stent location | Location of newly-detected tumors | Resection method | Pathological diagnosis (invasion depth) |
| 81 | Т | Sigmoid colon | EMR | Adenoma |
| 67 | RS | Cecum | ESD | Adenoma |
| | | Cecum | EMR | Adenoma |
| 75 | S | Descending colon | Surgery | Carcinoma (submucosal, 1500 µm) |
| 65 | Т | Ascending colon | EMR | Carcinoma (M) |
| 83 | D | Ascending colon | EMR | Adenoma |
| 77 | Α | Transverse colon | EMR | Adenoma |

T, transverse colon; RS, rectosigmoid colon; S, sigmoid colon; D, descending colon; A, ascending colon; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection: M. mucosal

It is important to note that colorectal cancer can be detected even in patients who undergo TCS between 6 months and several years before the diagnosis, namely post-colonoscopy colorectal cancer. Patients with a history of colorectal cancer surgery have a risk of developing post-colonoscopy colorectal cancer [10]. The Japanese Society for Cancer of the Colon and Rectum Guideline 2022 for the treatment of colorectal cancer recommends surveillance TCS 1 year after surgery [11]. The reported yield of colorectal cancer at surveillance colonoscopy 1 year after curative resection of colorectal primary cancer is 1.7% [12], and the yield could be even higher in patients with obstructive colorectal cancer who have not undergone preoperative evaluation of the entire colon. Thus, follow-up TCS is recommended within 6 months after surgery in patients who cannot undergo preoperative TCS owing to stenosis. In the present study, 87.4% of ER lesions were pathologically diagnosed as adenomas or adenocarcinomas. Considering that colonic adenoma may progress to adenocarcinoma, both adenocarcinomas and adenomas could be targets for preoperative ER. Therefore, it is important and effective to evaluate the entire colon, if possible, and to treat precancerous lesions before colorectal cancer surgery. In this study, only one patient with cancer detected by follow-up colonoscopy had to undergo a second surgery.

Being able to perform colonoscopy with a thin-diameter colonoscope through the SEMS provides very important advantages for the treatment of the patient, but colonic SEMS placement for the sole purpose of proximal colon observation or ER, but not for BTS, should be avoided. There were no complications associated with preoperative TCS and ER after SEMS placement in the present study. However, colonic SEMS placement is not recommended for patients with obstructive colorectal

cancer without obstructive symptoms in accordance with the Japanese Society for Cancer of the Colon and Rectum Guideline 2022 for the treatment of colorectal cancer. This is because the procedure-related perforation rate is reported to be 1.6%, and the rate of the risk of deviation is reported to be 1.3% [11].

The limitations of this study are small sample size, for there is no data for long-term course but only short follow-up after surgery. More statistical analysis of those patients by longer follow-up is necessary.

In conclusion, preoperative TCS and ER after SEMS placement was performed without complications, in this study. This approach permits preoperative evaluation of the entire colon and the treatment of precancerous lesions, which can avoid unnecessary multiple surgeries in patients with obstructive colorectal cancer.

Acknowledgements

We thank Jane Charbonneau, DVM, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

We thank Jane Charbonneau, DVM, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript. None of the authors has any Conflict of Interest regarding this report.

Authors' contributions

S.I. and S.H. and N.H. substantially contributed to the study conceptualization. Y.S. and D.Y. and T.S. and A.O. and H.F. and H.H. significantly contributed to data analysis and interpretation. E.I. substantially contributed to the manuscript drafting. All authors critically reviewed and revised the manuscript draft and approved the final version for submission.

Fundina

Not applicable.

Data Availability

The datasets generated during and analyzed during the current study are not publicly available due to due to restrictions for the availability of these data, which were used under the license for the current study but are available from the corresponding auther on reasonable request.

Declarations

Ethics approval and consent to participate

The need for informed consent as for this study was waived by the ethics committee Review Board of Clinical Research Institute, National Hospital Organization Kyushu Medical Center, because of the retrospective nature of study. However, all methods (SEMS placement, colonoscopy and endoscopic resection) were performed in accordance with the "Japanese Society for Cancer of the Colon and Rectum: JSCCR Guideline 2022 for the Treatment of Colorectal Cancer", and "Evidence-based Clinical practice Guidelines for Colonic Polyp 2020" for the Treatment of Colorectal Cancer. In addition, all experimental protocols were based on Declaration of Helsinki, and were approved by the ethics committee Review Board of Clinical Research Institute, National Hospital Organization Kyushu Medical Center.

Consent for publication

Not applicable.

Competing interests

None of the authors has any Conflict of Interest regarding this report. The datasets generated during and analyzed during the current study are not

publicly available due to due to restrictions for the availability of these data, which were used under the license for the current study but are available from the corresponding author on reasonable request. All treating or diagnostic methods for colorectal cancers and other neoplastic lesions were carried out in accordance with "Japanese Society for Cancer of the Colon and Rectum: JSCCR Guideline 2022 for the Treatment of Colorectal Cancer", and "Evidence-based Clinical practice Guidelines for Colonic Polyp 2020".

Author details

¹Department of Gastroenterology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-ku, Fukuoka 810-8563. Japan

²Department of Medicine and Bioregulatory Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

³Department of Gastroenterology, Kitakyushu Municipal Medical Center, Fukuoka, Japan

Received: 7 April 2023 / Accepted: 16 July 2023 Published online: 24 July 2023

References

- Alberto A, Roberto P, Giacomo LS, et al. Stent as bridge to surgery for leftsided malignant colonic obstruction reduces adverse events and stoma rate compared with emergency surgery: result of a systematic review and metaanalysis of randomized controlled trials. Gastrointest Endosc. 2018;86:416–26.
- Zeng WG, Liu MJ, Zhou ZX, et al. Stent as a bridge to surgery versus urgent surgery for malignant right colonic obstruction: a multicenter retrospective study. ANZ J Surg. 2021;91:E500–6.
- Kanaka S, Matsuda A, Yamada T, et al. Colonic stent as a bridge to surgery versus emergency resection for right-sided malignant large bowel obstruction: a meta-analysis. Surg Endosc. 2022;36:2760–70.
- Mora-Lopez L, Hidalgo M, Falco J, et al. Long-term outcomes of colonic stent as a "bridge to surgery" for left sided malignant large bowel obstruction. Surg Oncol. 2020;35:399–405.
- Yamaguchi T, Inatsugu N, Yoshikawa S, et al. A study on the usefulness of intraoperative colonoscopy in obstructive colorectal cancer. J Jpn Coloproctol. 2008;61:404–9.
- Maruo H, Tsuyuki H, Kojima T, et al. Total colonoscopy findings in obstructive colorectal cancer with stenting as a bridge to surgery (BTS). Jpn J Chemother. 2017;44:1238–40.
- Shimizuguchi R, Iizuka T, Takao A, et al. Efficacy of total colonoscopy after colonic stent placement. [In japanese]. Progress of Digestive Endoscopy. 2021;99:30–4.
- Tabata T, Koizumi K, Kuwata G, et al. Endoscopic observation of the proximal colon after colonic stent placement. Jpn J Gastroenterol. 2014;56:2407–13.
- Kim JS, Lee KM, Kim SW, et al. Preoperative colonoscopy through the colonic stent in patients with colorectal cancer obstruction. World J Gastroenterol. 2014;20:10570–6.
- Yamaguchi H, Fukazawa M, Minami H, et al. The relationship between post-colorectal cancer and quality indicators of colonoscopy: the latest single-center cohort study with a review of the literature. Intern Med. 2020:59:1481–8.
- 11. Japanese Society for Cancer of the Colon and Rectum.: JSCCR Guideline 2022 for the Treatment of Colorectal Cancer. 2022.
- 12. Lanschot MCJ, van Leerdam ME, Lansdrop-Vogelaar I, et al. Yield of surveillance colonoscopies 1 year after curative surgical colorectal cancer resections. Clin Gastroenterol Hepatol. 2019;17:2285–93.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.